SBC MEDICAL GROUP HOLDINGS INCRPRTD C/WTS 17/09/2029 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 43.35 M
I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q3, the actual value is USD 43.35 M.
EPS: As of FY2025 Q3, the actual value is USD 0.12.
EBIT: As of FY2025 Q3, the actual value is USD 15.81 M.
Segment Revenue
- Franchising Revenue: $9,929,387 for the three months ended September 30, 2025, a decrease of 36.71% from $15,688,528 for the same period in 2024.
- Procurement Revenue: $13,406,905 for the three months ended September 30, 2025, a decrease of 23.70% from $17,571,299 for the same period in 2024.
- Management Services Revenue: $9,462,183 for the three months ended September 30, 2025, a decrease of 21.87% from $12,110,764 for the same period in 2024.
- Rental Services Revenue: $6,219,645 for the three months ended September 30, 2025, an increase of 50.79% from $4,124,774 for the same period in 2024.
- Other Revenues: $4,335,115 for the three months ended September 30, 2025, an increase of 20.77% from $3,589,518 for the same period in 2024.
Operational Metrics
- Net Income: $12,833,326 for the three months ended September 30, 2025, an increase of 352.76% from $2,834,467 for the same period in 2024.
- Gross Profit: $30,611,487 for the three months ended September 30, 2025, a decrease of 29.20% from $43,239,090 for the same period in 2024.
- Operating Expenses: $14,730,247 for the three months ended September 30, 2025, a decrease of 49.90% from $29,404,487 for the same period in 2024.
Cash Flow
- Net Cash Used in Operating Activities: - $27,295,426 for the nine months ended September 30, 2025, compared to $27,886,231 provided by operating activities for the same period in 2024.
- Net Cash Provided by Investing Activities: $3,239,523 for the nine months ended September 30, 2025, compared to - $5,554,039 used in investing activities for the same period in 2024.
- Net Cash Provided by Financing Activities: $18,470,001 for the nine months ended September 30, 2025, compared to $11,584,038 for the same period in 2024.
Future Outlook and Strategy
- Core Business Focus: The company plans to maintain and strengthen its market position and brand in the cosmetic medical treatment management market in Japan, Vietnam, and Singapore, and grow its presence globally.
- Non-Core Business: The company is proceeding with the acquisition of common shares of Waqoo, Inc., a Japanese company listed on the Tokyo Stock Exchange, from the CEO of the company and other shareholders of Waqoo until the company obtains controlling interest in Waqoo.
